Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 1339-1345, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (44)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lebovitz, H. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lebovitz, H. E.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Arnold O. Beckman Conference
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1999;45:1339-1345.)
© 1999 American Association for Clinical Chemistry, Inc.

Articles

Type 2 Diabetes: An Overview

Harold E. Lebovitz

SUNY-Downstate Medical Center, 450 Clarkson Ave., Box 1205, Brooklyn, NY 11203. Fax 718-447-1558; e-mail hlebovitz{at}IBM.net

Type 2 diabetes is a heterogeneous disorder. Clinical expression of the disorder requires both genetic and environmental factors. One theory concerning its etiology is that it is the result of the evolution of a thrifty genotype that had survival benefits in the past but is detrimental in the current environment. An opposing theory is that it represents an adult metabolic response to fetal malnutrition. Hyperglycemia in type 2 diabetes results from absolute or relative insulin deficiency. Most often relative insulin deficiency is attributable to an inability to adequately compensate for insulin resistance. Insulin resistance may be caused by a variety of genetic or metabolic factors. The most common etiological factor in insulin resistance is central obesity. Insulin resistance is associated with a cluster of metabolic abnormalities that include glucose intolerance, hypertension, a unique dyslipidemia, a procoagulant state, and an increase in macrovascular disease. Clinical intervention studies have demonstrated that reduction in the chronic microvascular and macrovascular complications of type 2 diabetes requires treatment of hyperglycemia to achieve hemoglobin A1c <7.0%, blood pressure <=130/80 mmHg, and plasma LDL-cholesterol <=2.6 mmol/L (<=100 mg/dL). Oral antihyperglycemic agents increase endogenous insulin secretion, decrease insulin resistance, or lower postprandial plasma glucose rise by delaying absorption of complex carbohydrates. Long-term glycemic control in type 2 diabetes requires progressive, stepwise, combination treatment with oral agents and eventually combination treatment with oral agents and insulin.© 1999 American Association for Clinical Chemistry




The following articles in journals at HighWire Press have cited this article:


Home page
 Endocr. Rev.Home page
M.-A. Cornier, D. Dabelea, T. L. Hernandez, R. C. Lindstrom, A. J. Steig, N. R. Stob, R. E. Van Pelt, H. Wang, and R. H. Eckel
The Metabolic Syndrome
Endocr. Rev., December 1, 2008; 29(7): 777 - 822.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. de los Santos-Arteaga, S. A. Sierra-Dominguez, G. H. Fontanella, J. M. Delgado-Garcia, and A. M. Carrion
Analgesia Induced by Dietary Restriction Is Mediated by the {kappa}-Opioid System
J. Neurosci., December 3, 2003; 23(35): 11120 - 11126.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
U. Hochgeschwender, J. L. Costa, P. Reed, S. Bui, and M. B. Brennan
Altered Glucose Homeostasis in Proopiomelanocortin-Null Mouse Mutants Lacking Central and Peripheral Melanocortin
Endocrinology, December 1, 2003; 144(12): 5194 - 5202.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
D. E. Laaksonen, H.-M. Lakka, L. K. Niskanen, G. A. Kaplan, J. T. Salonen, and T. A. Lakka
Metabolic Syndrome and Development of Diabetes Mellitus: Application and Validation of Recently Suggested Definitions of the Metabolic Syndrome in a Prospective Cohort Study
Am. J. Epidemiol., December 1, 2002; 156(11): 1070 - 1077.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
M. P. Mattson, S. L. Chan, and W. Duan
Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior
Physiol Rev, July 1, 2002; 82(3): 637 - 672.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. I. Albarrak, S. D. Luzio, L. J. Chassin, R. A. Playle, D. R. Owens, and R. Hovorka
Associations of Glucose Control with Insulin Sensitivity and Pancreatic {beta}-Cell Responsiveness in Newly Presenting Type 2 Diabetes
J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 198 - 203.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
C. M. Doak, L. S. Adair, C. Monteiro, and B. M. Popkin
Overweight and Underweight Coexist within Households in Brazil, China and Russia
J. Nutr., December 1, 2000; 130(12): 2965 - 2971.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.